Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Sanfelippo MJ, Sennet J, McMahon EJ (2000) Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant. WMJ 99:43–62

  2. 2.

    Rosborough TK, Shepherd MF (2004) Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 24:838–842

  3. 3.

    Moll S, Ortel TL (1997) Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127:177–185

  4. 4.

    Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM (2001) Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant—results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 115:672–678

  5. 5.

    Lawrie AS, Mackie IJ, Purdy G, Machin SJ (2001) Effect of lupus anticoagulants on INR with different thromboplastins. Blood Coagul Fibrinolysis 12:221

  6. 6.

    Robert A, Le Querrec A, Delahousse B, Caron C, Houbouyan L, Boutiere B, Horellou MH, Reber G, Sie P (1998) Control of oral anticoagulation in patients with the antiphospholipid syndrome–influence of the lupus anticoagulant on international normalized ratio. groupe methodologie en hemostase du groupe d’etudes sur l’hemostases et la thrombose. Thromb Haemost 80:103–199

  7. 7.

    Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI (1994) The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 120:552–558

  8. 8.

    Mielicki WP, Gordon SG (1993) Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. Blood Coagul Fibrinolysis 4:441–446

  9. 9.

    Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349:1133–1138

  10. 10.

    Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D’Angelo A, Tognoni G, Barbui T (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853

Download references

Author information

Correspondence to Siva S. Ketha.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ketha, S.S., Pruthi, R.K., McBane, R.D. et al. Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation. J Thromb Thrombolysis 37, 532–535 (2014). https://doi.org/10.1007/s11239-013-0949-1

Download citation

Keywords

  • Warfarin
  • Mitral Valve
  • International Normalize Ratio
  • Prothrombin Time
  • Argatroban